Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SYN-004

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Recombinant Proteinsbeta-Lactamase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
BACKGROUND Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of… Expand
2017
2017
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
2017
2017
SYN‐004 (ribaxamase), an oral beta‐lactamase, mitigates antibiotic‐mediated dysbiosis in a porcine gut microbiome model
To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic‐mediated damage. 
2017
2017
SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an… Expand
2017
2017
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to… Expand
2016
2016
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1…
BackgroundSYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
Nonclinical Safety Assessment of SYN-004
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2015
2015
Tu2054 SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs
Antibiotics (abx) that are excreted into the intestine, such as ceftriaxone (CRO), can damage the microflora and lead to serious… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE